Abstract:Abstract Background: The limitations of chemotherapeutic applications are often imposed by dose-related toxicity and the emergence of therapeutic resistance. Fisetin, a naturally occurring flavonoid, has demonstrated anticancer properties in various cancer types. Despite its proven effectiveness against cancer, the molecular target of fisetin remains unknown. Methods: Our study focused on understanding how fisetin and chemotherapy work together to inhibit the growth and survival of human HNC. We conducted in silico, in vitro and in vivo investigations. We employed target prediction, kinase profiling, transcriptome analysis and tumor xenograft to identify the chemosensitivity efficacy and mechanism of fisetin. Results: In-silico target prediction suggested that fisetin might target multiple kinases. Based on this lead, we have screened fisetin for different kinase inhibition activities and found that it inhibits multiple CDKs including CDK1, 2, 4, 5 and 6 at nanomolar concentration. To test its cellular activity, we have selected the head and neck cancer (HNC) model and found that fisetin treatment strongly inhibited cell proliferation and arrested the HNC cells in G1 phase followed by apoptotic cell death. In tumor xenograft experiment, we found that oral fisetin treatment inhibited the FaDu and SAS tumor growth in the athymic mouse model. Transcriptome analysis on FaDu and SAS cell lines indicated that fisetin treatment significantly modulates pathways associated with cell cycle progression and regulation. These pathways include cellular assembly, DNA replication, cell death, and cell morphology. Pretreatment of HNC cells with fisetin improved the effectiveness of chemotherapy drugs including cisplatin, 5-fluorouracil, and docetaxel. Consistent with this, fisetin pre-treated cells showed elevated levels of cellular and mitochondrial ROS followed by the activation of caspases and apoptosis induction when compared with that in control cells after cisplatin, 5-FU, or docetaxel treatment. Conclusion: These results imply that fisetin has the potential to be utilized as a multi-kinase inhibitor in cancer cells. The study revealed that fisetin has a strong potential for increasing the sensitivity of cancer cells to chemotherapy. Citation Format: Dhanir Tailor, Deepali Mishra, Sanjay V. Malhotra, Rana P. Singh. Fisetin, a multi-kinase inhibitor enhances chemotherapeutic sensitivity in head and neck cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4617.

ZC3H13-mediated N6-methyladenosine modification of <i>PHF10</i> is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer

Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation

Fisetin Disrupts Mitochondrial Homeostasis Via Superoxide Dismutase 2 Acetylation in Pancreatic Adenocarcinoma.

Post-translational Modification of CDK1–STAT3 Signaling by Fisetin Suppresses Pancreatic Cancer Stem Cell Properties

N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Fisetin Inhibits the Proliferation, Migration and Invasion of Pancreatic Cancer by Targeting PI3K/AKT/mTOR Signaling

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC

Fisetin enhances cisplatin sensitivity in renal cell carcinoma via the CDK6/PI3K/Akt/mTOR signaling pathway

Identification of VPS34-PI(3)P-FEN1-mediated DNA repair pathway as a potential drug target to overcome chemoresistance

Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics

Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells

Abstract 7109: Fasn inhibition enhances the efficacy of chemotherapy by inhibiting DNA damage response in colorectal cancer

Retraction Note: Suppression of Fumarate Hydratase Activity Increases the Efficacy of Cisplatin-Mediated Chemotherapy in Gastric Cancer

PTEN-mediated dephosphorylation of 53BP1 confers cellular resistance to DNA damage in cancer cells

A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells

Enhancing Chemotherapy Sensitivity by Targeting PcG Via the ATM/p53 Pathway

CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes

Abstract 4617: Fisetin, a multi-kinase inhibitor enhances chemotherapeutic sensitivity in head and neck cancer

MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin